DnB Asset Management
DRUG

DnB Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

DnB Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
4,822
+381
+9% +$29.9K ﹤0.01% 973
2026
Q1 		$324K Buy
+4,441
New +$357K ﹤0.01% 933

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

DnB Asset Management's DRUG Position: Q2 2026 in Review

DnB Asset Management increased its Bright Minds Biosciences (DRUG) stake by 8.6% in Q2 2026, buying an estimated $29.9K and bringing the position to 4,822 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

DnB Asset Management first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • DnB Asset Management held 4,822 shares of Bright Minds Biosciences worth $339K as of Q2 2026.
  • DnB Asset Management bought 381 Bright Minds Biosciences shares in Q2 2026, an estimated $29.9K.
  • Bright Minds Biosciences made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #973 holding.
  • DnB Asset Management first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.